MedPath

Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection

Phase 4
Not yet recruiting
Conditions
Ulcers, Gastric
Interventions
Registration Number
NCT06526455
Lead Sponsor
Shicai Ye
Brief Summary

The purpose of this clinical trial is to find out the effectiveness of voronasan in combination with aluminum phosphate gel in the treatment of post-operative ESD ulcers. It will also find out about the safety of vunorasan in combination with aluminum phosphate gel. The main questions it aims to answer are:

1. Do vonorasan in combination with aluminum phosphate gel clinically effective in the treatment of post-operative ESD ulcers?

2. What medical problems do participants have when taking drug vonorasan in combination with aluminum phosphate gel? Researchers compared the drug voransen in combination with aluminum phosphate gel to esomeprazole in combination with aluminum phosphate gel to see if voransen in combination with aluminum phosphate gel worked better for post-operative ESD ulcers.

Participants will:

Intravenous lansoprazole 1-3 days after ESD and oral voronasan combined with aluminum phosphate gel or esomeprazole combined with aluminum phosphate gel 3-56 days after ESD.

Record their symptoms, endoscopic ulcer grading, ulcer size and Calculate ulcer healing rate at weeks 2 and 8.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
196
Inclusion Criteria
  • Meets surgical indications for ESD
  • Age 18-70 years, regardless of gender
  • Normal coagulation
  • ESD Postoperative ulcers ≤3cm
  • Voluntary participation in the study
Exclusion Criteria
  • Patients with severe complications or failure to achieve curative resection after gastric ESD surgery need supplementary surgery
  • Women who are pregnant or breastfeeding, or who may conceive during clinical trials
  • The patient has other serious organic diseases that affect the evaluation of the study, such as severe liver disease, heart disease, renal disease, malignant neoplasm and alcoholism
  • Patients who need to take antiplatelet and NSAIDS drugs for a long period of time
  • Co-administration of unspecified anti-ulcer drugs during the trial period;Allergic reactions to vornoxan, aluminium phosphate gel or esomeprazole
  • Patients with no capacity for autonomous behaviors, unable to correctly express their main complaint, such as those with mental illness, severe neurosis, and unable to cooperate with this experiment
  • ESD Postoperative ulcers >3cm

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatment groupVonoprazanVonorasan、tablet、20mg、qd、Days 3 to 56
Control groupEsomeprazoleEsomeprazole 、tablet、20mg、Days 3 to 56
Primary Outcome Measures
NameTimeMethod
Rate of ulcer reduction2nd and 8th week post-dose

Ulcer area = maximum diameter of the ulcer \* perpendicular line of the maximum diameter (mm2) The rate of ulcer reduction at 2 weeks = \[(area of the initial ulcer - area of the ulcer at 2 weeks)/area of the initial ulcer\]\*100% The rate of ulcer reduction at 8 weeks = \[ (area of the initial ulcer - area of the ulcer at 8 weeks)/area of the initial ulcer\]\*100% Ulcer area = maximum diameter of the ulcer \* perpendicular line of the maximum diameter (mm2) The rate of ulcer reduction at 2 weeks = \[(area of the initial ulcer - area of the ulcer at 2 weeks)/area of the initial ulcer\]\*100% The rate of ulcer reduction at 8 weeks = \[ (area of the initial ulcer - area of the ulcer at 8 weeks)/area of the initial ulcer\]\*100%

Secondary Outcome Measures
NameTimeMethod
Rate of ulcer healing2nd and 8th week post-dose

Healing rate = number of cases with scarring/total number of cases × 100 per cent

Size of ulcer2nd and 8th week post-dose

Ulcer area = maximum diameter of the ulcer \* perpendicular line of the maximum diameter (mm2)

Postoperative symptom relief rate2th week post-dose

Number of persons in remission/total

Rate of bumpy2nd and 8th week post-dose

Rate of bumpy= number of cases that have occurred/total number of cases × 100 per cent

Rate of delayed hemorrhage2th week post-dose

Rate of delayed hemorrhage=Number of haemorrhages/total

Quality of ulcer healing2nd and 8th week post-dose

Scoring using the Ulcer Healing Scoring Scale,the highest score is 3 and the lowest is 1, with higher scores indicating better ulcer healing

Trial Locations

Locations (4)

Yellow River Sanmenxia Hospital

🇨🇳

Sanmenxia, Henan, China

The First Affiliated Hospital of Jinan University

🇨🇳

Guangzhou, Guangdong, China

Maoming People's Hospital

🇨🇳

Maoming, Guangdong, China

The First Hospital of Guangzhou Medical University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath